Loading clinical trials...
Loading clinical trials...
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Conditions
Interventions
Irinotecan + Carboplatin
irinotecan + Carboplatin + erbitux
Locations
59
United States
Birmingham Hematology and Oncology
Birmingham, Alabama, United States
Hematology Oncology Asscociates
Phoenix, Arizona, United States
Northern AZ Hematology & Oncology Assoc
Sedona, Arizona, United States
Rocky Mountain Cancer Center-Rose
Denver, Colorado, United States
Northwestern Connecticut Oncology Hematology Associates
Torrington, Connecticut, United States
Melbourne Internal Medicine Associates
Melbourne, Florida, United States
Start Date
July 28, 2005
Primary Completion Date
December 1, 2025
Completion Date
December 1, 2026
Last Updated
January 29, 2025
NCT05468034
NCT07347600
NCT07085767
NCT05660083
NCT07354022
NCT02422641
Lead Sponsor
US Oncology Research
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions